JP2006505564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006505564A5 JP2006505564A5 JP2004544891A JP2004544891A JP2006505564A5 JP 2006505564 A5 JP2006505564 A5 JP 2006505564A5 JP 2004544891 A JP2004544891 A JP 2004544891A JP 2004544891 A JP2004544891 A JP 2004544891A JP 2006505564 A5 JP2006505564 A5 JP 2006505564A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- sarm
- nhcor
- conhr
- snr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 88
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 86
- 125000000217 alkyl group Chemical group 0.000 claims 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 48
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 28
- 239000000126 substance Substances 0.000 claims 28
- 101100149678 Caenorhabditis elegans snr-3 gene Proteins 0.000 claims 24
- 125000004122 cyclic group Chemical group 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 24
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 20
- 125000003342 alkenyl group Chemical group 0.000 claims 20
- 125000004982 dihaloalkyl group Chemical group 0.000 claims 20
- 125000001188 haloalkyl group Chemical group 0.000 claims 20
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 20
- 230000000694 effects Effects 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 210000002307 prostate Anatomy 0.000 claims 14
- 230000003042 antagnostic effect Effects 0.000 claims 12
- 230000008878 coupling Effects 0.000 claims 12
- 238000010168 coupling process Methods 0.000 claims 12
- 238000005859 coupling reaction Methods 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 12
- 210000003205 muscle Anatomy 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 8
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 8
- 239000003098 androgen Substances 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 210000000988 bone and bone Anatomy 0.000 claims 8
- 210000003169 central nervous system Anatomy 0.000 claims 8
- 239000013078 crystal Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
- 239000007788 liquid Substances 0.000 claims 8
- 239000002207 metabolite Substances 0.000 claims 8
- 239000008188 pellet Substances 0.000 claims 8
- -1 polymorphs Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000007787 solid Substances 0.000 claims 8
- 201000004384 Alopecia Diseases 0.000 claims 6
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 6
- 206010058359 Hypogonadism Diseases 0.000 claims 6
- 208000029725 Metabolic bone disease Diseases 0.000 claims 6
- 206010027940 Mood altered Diseases 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 206010049088 Osteopenia Diseases 0.000 claims 6
- 208000001132 Osteoporosis Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 201000001880 Sexual dysfunction Diseases 0.000 claims 6
- 231100000360 alopecia Toxicity 0.000 claims 6
- 208000007502 anemia Diseases 0.000 claims 6
- 230000001149 cognitive effect Effects 0.000 claims 6
- 230000003247 decreasing effect Effects 0.000 claims 6
- 201000001881 impotence Diseases 0.000 claims 6
- 230000007510 mood change Effects 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 231100000872 sexual dysfunction Toxicity 0.000 claims 6
- 229940124011 Androgen receptor agonist Drugs 0.000 claims 4
- 229940123407 Androgen receptor antagonist Drugs 0.000 claims 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 4
- 230000001270 agonistic effect Effects 0.000 claims 4
- 239000003936 androgen receptor antagonist Substances 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 239000006071 cream Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 4
- 239000012530 fluid Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 4
- 150000004677 hydrates Chemical class 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 239000000829 suppository Substances 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 239000003826 tablet Substances 0.000 claims 4
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000003405 preventing effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000001603 reducing effect Effects 0.000 claims 2
- 230000009467 reduction Effects 0.000 claims 2
- 208000001076 sarcopenia Diseases 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 claims 1
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 0 CCC*C(C)(C)C(C1)C(C)[C@@]1C(*)[C@@](C1)C2C3C1C(C)C2C3 Chemical compound CCC*C(C)(C)C(C1)C(C)[C@@]1C(*)[C@@](C1)C2C3C1C(C)C2C3 0.000 description 4
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41833602P | 2002-10-16 | 2002-10-16 | |
| PCT/US2003/032513 WO2004035739A2 (en) | 2002-10-16 | 2003-10-14 | Treating androgen decline in aging male (adam)-associated conditions with sarms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006505564A JP2006505564A (ja) | 2006-02-16 |
| JP2006505564A5 true JP2006505564A5 (enExample) | 2006-08-17 |
Family
ID=32107914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004544891A Pending JP2006505564A (ja) | 2002-10-16 | 2003-10-14 | Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050080054A1 (enExample) |
| EP (1) | EP1558233A2 (enExample) |
| JP (1) | JP2006505564A (enExample) |
| CN (1) | CN1726020A (enExample) |
| AU (1) | AU2003287079A1 (enExample) |
| CA (1) | CA2501874A1 (enExample) |
| IL (1) | IL168046A0 (enExample) |
| TW (1) | TW200502250A (enExample) |
| WO (1) | WO2004035739A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
| US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
| US8309603B2 (en) * | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| FI20030958A0 (fi) * | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
| MXPA06002462A (es) * | 2003-10-14 | 2006-06-20 | Gtx Inc | Tratamiento de desordenes relacionados con huesos con moduladores del receptor de angrogeno selectivo. |
| ATE485300T1 (de) | 2004-07-16 | 2010-11-15 | Sunesis Pharmaceuticals Inc | Als aurora-kinase-inhibitoren nutzbare thienopyrimidine |
| US20090215731A1 (en) | 2005-10-19 | 2009-08-27 | Chavah Pty Ltd. | Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US8791158B2 (en) | 2010-01-11 | 2014-07-29 | Gtx, Inc. | Methods of treating meibomian gland dysfunction |
| JP6055215B2 (ja) | 2012-06-29 | 2016-12-27 | キーサイト テクノロジーズ， インク． | インピーダンス測定方法及び測定装置 |
| CN107405353B (zh) | 2014-10-22 | 2021-07-30 | 哈瓦赫治疗有限公司 | 降低乳房摄影乳腺密度和/或乳腺癌风险的方法 |
| SG11201803260PA (en) | 2015-10-22 | 2018-05-30 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| JP2022535827A (ja) | 2019-06-03 | 2022-08-10 | ハバ セラピューティクス ピーティワイ エルティディ | アンドロゲン剤およびアロマターゼ阻害剤の送達のための医薬製剤およびシステム、ならびに使用のための方法 |
| WO2025102293A1 (zh) * | 2023-11-16 | 2025-05-22 | 北京脑科学与类脑研究所 | 神经活性雄激素受体调节剂及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875229A (en) * | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
| US4139638A (en) * | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
| DE2862100D1 (en) * | 1977-10-12 | 1983-01-05 | Ici Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
| US4191775A (en) * | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
| NZ197008A (en) * | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
| JPS57171904A (en) * | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
| LU88769I2 (fr) * | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
| GB8617652D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
| US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| US5609849A (en) * | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
| US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| US6017924A (en) * | 1996-06-27 | 2000-01-25 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
| WO1998053826A1 (en) * | 1997-05-30 | 1998-12-03 | The University Of Tennessee Research Corporation | Non-steroidal agonist compounds and their use in male hormone therapy |
| AU7723198A (en) * | 1997-06-04 | 1998-12-21 | University Of Tennessee Research Corporation, The | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
| US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
| US8008348B2 (en) * | 2001-12-06 | 2011-08-30 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
| AU2001285230C1 (en) * | 2000-08-24 | 2008-03-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| IL154425A0 (en) * | 2000-08-24 | 2003-09-17 | Univ Tennessee Res H Corp | Selective androgen receptor modulators and methods of use thereof |
| US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| IL162340A0 (en) * | 2001-12-06 | 2005-11-20 | Gtx Inc | Treating muscle wasting with selective androgen receptor modulators |
| US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
| DK1480634T3 (da) * | 2002-02-07 | 2011-11-14 | Univ Tennessee Res Foundation | Selektive androgenreceptormodulatorer (SARM) til behandling af benign prostatahyperplasi |
| WO2004034978A2 (en) * | 2002-10-15 | 2004-04-29 | Gtx, Inc. | Treating obesity with selective androgen receptor modulators |
| CA2514024A1 (en) * | 2003-01-22 | 2004-08-05 | Gtx Inc. | Treating androgen deficiency in female (adif)-associated conditions with sarms |
| MXPA06002462A (es) * | 2003-10-14 | 2006-06-20 | Gtx Inc | Tratamiento de desordenes relacionados con huesos con moduladores del receptor de angrogeno selectivo. |
| EP1931199A4 (en) * | 2005-08-31 | 2009-07-29 | Univ Tennessee Res Foundation | COMBATING NURSE DISEASE, BURNS, WOUNDS AND BACKMARK INJURIES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS |
-
2003
- 2003-10-14 WO PCT/US2003/032513 patent/WO2004035739A2/en not_active Ceased
- 2003-10-14 CA CA002501874A patent/CA2501874A1/en not_active Abandoned
- 2003-10-14 JP JP2004544891A patent/JP2006505564A/ja active Pending
- 2003-10-14 AU AU2003287079A patent/AU2003287079A1/en not_active Abandoned
- 2003-10-14 CN CNA2003801063099A patent/CN1726020A/zh active Pending
- 2003-10-14 EP EP03777600A patent/EP1558233A2/en not_active Withdrawn
- 2003-10-14 US US10/683,161 patent/US20050080054A1/en not_active Abandoned
- 2003-10-16 TW TW092128721A patent/TW200502250A/zh unknown
-
2005
- 2005-04-14 IL IL168046A patent/IL168046A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006511486A5 (enExample) | ||
| JP2006516286A5 (enExample) | ||
| JP2006505564A5 (enExample) | ||
| JP2006518328A5 (enExample) | ||
| JP2006514098A5 (enExample) | ||
| JP2009506119A5 (enExample) | ||
| RU2015104780A (ru) | Способ лечения андроген-рецептора(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов(sarm) | |
| JP2006506369A5 (enExample) | ||
| US7772433B2 (en) | SARMS and method of use thereof | |
| JP2005526741A5 (enExample) | ||
| AU2008239601B2 (en) | Selective androgen receptor modulators for treating diabetes | |
| US8110562B2 (en) | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof | |
| CA2538095A1 (en) | Selective androgen receptor modulators and methods of use thereof | |
| US20110237664A1 (en) | Selective androgen receptor modulators for treating diabetes | |
| JP2006505563A (ja) | 選択的アンドロゲン受容体調節剤による肥満治療 | |
| CA2477737A1 (en) | Multi-substituted selective androgen receptor modulators and methods of use thereof | |
| CA2621189A1 (en) | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators | |
| JP2007508386A5 (enExample) | ||
| CA2535953A1 (en) | Treating bone-related disorders with selective androgen receptor modulators | |
| CA2551737A1 (en) | Helix 12 directed steroidal pharmaceutical products | |
| WO2004064747A2 (en) | Treating androgen deficiency in female (adif)-associated conditions with sarms | |
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| CN109843872A (zh) | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 | |
| JP2007513998A5 (enExample) | ||
| RU2015147509A (ru) | Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы |